An observational study in Tobacco Use, E-Cigarette Use and Cardiovascular Diseases, sponsored by University of Wisconsin, Madison. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-21.
Sponsored by University of Wisconsin, Madison · Observational
This study is designed to enhance the understanding of the possible health effects of e-cigarette use by relating the acute and long-term use of e-cigarettes and conventional cigarettes ("products") to well-validated cardiovascular and pulmonary disease biomarkers. Participants will be enrolled in 3 groups: exclusive e-cigarette users, exclusive cigarette smokers, and a control group of never-users. Participants can expect up to 4 weeks of study participation.
E-cigarette use is increasing rapidly in the United States, especially amongst youth, underscoring the vital need to improve understanding of its health risks. Relevant data could inform policy, guide public health and clinical intervention efforts, and inform individuals who might use or who are using this product. This research will significantly enhance the understanding of the possible health effects of e-cigarette use by relating the acute and long-term use of e-cigarettes and conventional cigarettes ("products") to well-validated cardiovascular and pulmonary disease biomarkers. 3 different "use-groups" of participants will be enrolled: exclusive e-cigarette users (n=165), exclusive cigarette smokers (n=165), and a "control" group of never-users (n=110). These groups reflect the primary decisions that people can make regarding their future tobacco use: to continue to smoke cigarettes, to switch to e-cigarettes, or to avoid tobacco use entirely. It is essential that smokers and health care providers have accurate information on the health effect of these choices.
[Additionally, 100 participants will be invited to be part of an epigenetics sub-study (50 E-cig users, 25 smokers and 25 controls), prior to smoking, an additional 16 ml of blood will be collected in Vacutainer cell separation tubes for peripheral blood monocyte (PBMC) Isolation containing sodium citrate.]
Product use will be related to well-validated biomarkers that sensitively and reproducibly reflect mechanisms, injury, and/or future risk related to cardiovascular or pulmonary disease. Biomarkers will be related to: 1) acute product use in the laboratory (exposure challenges), 2) lifetime history of product use, and/or 3) real-time measures of product use in participants' daily lives. The primary cardiovascular biomarkers are brachial artery flow-mediated dilation (a measure of endothelial function) and carotid intima-media thickness, a measure of subclinical arterial injury and atherosclerosis. The primary pulmonary disease biomarkers will be measures of lung volumes and flow rates (Forced Expiatory Volume exhaled in the first second (FEV1), Forced vital capacity (FVC), FEV1/FVC) obtained by spirometry. Treadmill exercise stress testing will be performed (to assess aerobic fitness), electrocardiography (to measure heart rate variability, HRV), and measure heart rate, blood pressure, lipids, HgbA1c, and inflammation/oxidation markers (leukocyte count, C-reactive protein, urinary F2 isoprostanes and exhaled nitric oxide). This research will show how product use-groups differ in response to acute product use and long-term use as they are related to key cardiovascular and pulmonary biomarkers. Objective measures of product use include exhaled CO and plasma nicotine/cotinine and urinary nicotine/cotinine concentrations. History of product use within use-groups will be related to biomarker status.
The proposed research will yield vital and comprehensive data regarding product use, subclinical arterial injury, atherosclerosis burden, arterial and pulmonary function, cardiac and aerobic fitness, cardiac autonomic regulation, systemic and pulmonary inflammation, and oxidative stress, as well as other key outcomes. These data will serve as a foundation for future longitudinal investigations of e-cigarette health effects and will inform public policy decisions, clinical intervention, and patient guidance regarding e-cigarettes.
140 studies on the registry are indexed under Tobacco Use; 68 are open to participants now.
Browse Tobacco Use studies →University of Wisconsin, Madison is the lead sponsor of 1,182 studies on the registry; 180 are open to participants now.
Of its 156 completed or terminated interventional studies of FDA-regulated products, 118 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
165 exclusive E-cig users, 165 exclusive cigarette smokers, and 110 never-users will be enrolled. Tobacco product use will be examined via time-line follow-back use-history measures, real-time measures, and lab measures. Potential participants will be assessed for eligibility via a phone screen. Because biomarker status may be affected by age and sex, groups will be stratified equally for gender (48/52 male/female) and age (≤35/>35 years).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Specific to Exclusive Smokers:
Specific to Exclusive E-cig users:
Specific to Never-users
Exclusion Criteria:
Smokes Daily; \>/= 5 cigarettes/day for last 6 months
Behavioral: Cigarettes
E-cig usage \>/= 5 days/week for last 3 months
Behavioral: E-Cigarettes
\< 100 cigarettes in lifetime, none for \> 5 years; \< 3 E-cig usage in lifetime
smokes daily
E-cigarette usage \>/= 5 days/week
Also known as: E-cig, Vape
Brachial Artery Flow-Mediated Dilation (FMD)- Pre Challenge
Brachial Artery Flow-Mediated Dilation is a primary cardiovascular biomarker and a measure of endothelial function that will be assessed before and after an acute exposure challenge. These are pre-challenge values. Ultrasound based changes in brachial artery diameter after a forearm cuff occlusion (250mmHg) for 5 minutes. FMD is the percent change in brachial diameter measured 60 to 90 seconds post cuff release compared to its resting diameter. A higher % dilation is an indication of better endothelial function.
Time frame: V2 up to 4 weeks from enrollment visit, fasting
Forced Expiratory Volume (FEV1)- Pre Challenge
FEV1 is a primary measure of pulmonary disease obtained by spirometry that will be assessed before and after an acute exposure challenge. These are per-challenge values
Time frame: V2 up to 4 weeks from enrollment visit , fasting, pre challenge session
Carotid Intima-Media Thickness (IMT)
Carotid Intima-Media Thickness is a cardiovascular biomarker and a measure of sub-clinical arterial injury and atherosclerosis as a result of chronic exposure. IMT will be measured via ultrasonography.
Time frame: V2 up to 4 weeks from enrollment visit, only done pre-challenge
Changes in Systolic Blood Pressure Pre- and Post-challenge.
Visit 2 was scheduled up to 4 weeks from enrollment visit, fasting.. They came in the morning after 8 hours of fasting and refraining from nicotine products. Systolic blood pressure (left brachial artery using an oscillometric method) was measured supine, after 10 minutes rest ("Pre") and repeated after they underwent smoking or vaping changes. The "post challenge" blood pressures were recorded 15-20 minutes post end of exposure. For controls, all measurements were repeated in the same order after a 10 minute break.
Time frame: During Visit 2 (1 - 4 weeks post enrollment) before and after smoking/vaping challenge and for controls after a 10 minute break
Changes in Diastolic Blood Pressure Pre- and Post-challenge.
Participants returned for V2 up to 4 weeks from enrollment visit, fasting. They came in the morning after 8 hours of fasting and refraining from nicotine products. Diastolic blood pressure (left brachial artery using an oscillometric method) was measured supine, after 10 minutes rest ("Pre") and repeated after they underwent smoking or vaping changes. The "post challenge" blood pressures were recorded 15-20 minutes post end of exposure. For controls, all measurements were repeated in the same order after a 10 minute break.
Time frame: before and after smoking/vaping challenge during Visit 2 (up to 4 weeks from enrollment)
Changes in Heart Rate Pre- and Post-challenge.
Visit 2 was scheduled up to 4 weeks from enrollment visit, fasting. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge heart rate measured supine, after 10 minutes rest from blood pressure monitor (dinamap). The post challenge heart rates were recorded 15-20 minutes post end of exposure to smoking or vaping challenge completion or in the case of controls after a 10 minute break.
Time frame: Before and after smoking/vaping challenge during Visit 2 (up to 4 weeks from enrollment)
Changes in Brachial Artery Diameter Pre- and Post-challenge
Visit 2 was scheduled up to 4 weeks from enrollment visit. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge brachial artery diameter imaged with ultrasound after resting supine for 10 minutes before and repeated 15-20 minutes after smoking/vaping challenge ended. or in the case of controls after a 10 minute break.
Time frame: before and after smoking/vaping challenge during Visit 2 (up to 4 weeks from enrollment)
Changes in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge
Visit 2 was scheduled up to 4 weeks from enrollment visit. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge ultrasound of brachial artery diameter imaged with ultrasound after resting supine for 10 minutes before and repeated 15-20 minutes after smoking/vaping challenge ended. or in the case of controls after a 10 minute break. The FMD protocol includes measuring % change in resting diameter after 60-90 seconds post fore-arm cuff occlusion release.
Time frame: Testing was done after 10 minutes rest and fasting for pre- and post-challenge. The post challenge FMD were recorded 15-20 minuted after end of exposure (up to 4 weeks from enrollment)
Changes in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge
Expressed as a percentage of beats (supine recordings had be 5 minutes or longer to be valid). We used the SphygmoCor system for these recordings (Atcor medical). Participants attended V2 1-2 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability was recorded supine for 10 minutes or more, pre and post smoking/vaping challenge. For controls is was repeated after a 10-minute break.
Time frame: During V2 (scheduled up to 4 weeks from enrollment) and obtained after 10 minutes of supine rest, before and after smoking/vaping challenge
Changes in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge
Participants attended V2 up to 4 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability was recorded supine for 10 minutes or more, pre and post smoking/vaping challenge. For controls it was repeated after a 10 minute break.
Time frame: heart rate variability recordings of at least 10 minutes per-challenge and 15 minutes post-challenge (up to 4 weeks from enrollment)
Changes in Heart Rate Variability Standing Ratio Pre- and Postchallenge
We used the SphygmoCor system for these recordings (Atcor medical). Participants attended V2 up to 4 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability standing ratio was assessed pre and post smoking/vaping challenge. For controls is was repeated after a 10-minute break. Ratio between maximal heart rate after abrupt standing from a supine position and the subsequent lowest heart rate value within 40 seconds of peak.
Time frame: Ratio was measured pre- and post- smoking/vaping challenge after completion of the 10 minutes of heart rate variability measures (up to 4 weeks from enrollment)
Changes in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge
maximum amount of air that the subject can forcibly expel during the first second following maximal inhalation, expressed as a percentage of the predicted normal values in the population. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
Time frame: before and after smoking/vaping challenge during Visit 2 (1-4 weeks after enrollment visit)
Changes in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge.
Amount of air that can be forcibly exhaled after taking the deepest breath possible expressed as a predicted percentage from the normal population. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
Time frame: before and after smoking/vaping challenge during Visit 2 Visit 2 which was scheduled 1 to 4 weeks from enrollment visit, fasting
Changes in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge
The post challenge spirometry was recorded \<15 minutes post end of exposure. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
Time frame: before and after smoking/vaping challenge during Visit 2 (1-4 weeks after enrollment visit)
Changes in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge
Participants attended Visit 2 (1-4 weeks after enrollment visit). They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
Time frame: Spirometry performed pre-challenge and within 15 minutes post-challenge (up to 4 weeks from enrollment)
Changes in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge
Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge FeNO was obtained sitting and repeated within 15 minutes after smoking/vaping challenge.
Time frame: before and after less than 15 minutes from smoking/ vaping product (up to 4 weeks from enrollment)
Heart Rate (HR)
Heart Rate pre-acute exposure challenge was obtained after resting supine for 10 minutes during V2 in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior.
Time frame: Participants attended V2 generally 1-4 weeks after enrollment with a window that allowed up to 4 weeks after enrollment
Heart Rate Variability (HRV) - Pre Product Use Challenge
Heart Rate Variability PNN50(%) measured before an exposure challenge. Participants attended visit 2 fasting and refraining from nicotine for at least 8 hours.
Time frame: V2 two was generally scheduled 1-4 weeks after enrollment visit with a window up to 4 weeks. HRV measures obtained after resting supine for 10 minutes
Systolic Blood Pressure (BP)
Blood Pressure measured using the oscillometric technique before an acute exposure challenge following standardized protocol. After resting supine for 10 minutes blood pressure was measured on both arms and the average of the last two values was used.
Time frame: V2 was up to 4 weeks from enrollment visit, after resting supine for 10 minutes
Forced Vital Capacity (FVC)
Forced Vital Capacity is a measure of how much air can be exhaled forcefully obtained by spirometry pre acute exposure challenge.
Time frame: recordings obtained during V2 in the morning, fasting and refraining from nicotine for at least 8 hours. This visit was generally 1-2 weeks after enrollment date with a window up to 4 weeks
Fractional Exhaled Nitric Oxide (FeNO)
Fractional Exhaled Nitric Oxide is a measure of airway inflammation measured before an acute exposure challenge.
Time frame: recordings obtained during V2 in the morning, fasting and refraining from nicotine for at least 8 hours. This visit was generally 1-2 weeks after enrollment date with a window up to 4 weeks
Autonomic Measures - RMSSD
Root mean square of standard deviation of rr intervals. Obtained fasting and refraining from nicotine exposure using the Sphymocor system. We used 10 or more minutes of supine data to derive heart rate variability measures.
Time frame: v2 was generally 1-2 weeks after enrollment visit, with a window up to 4 weeks from V1
Arterial Pulse Wave Analysis (PWA), Augmentation Index (at 75 Bpm, %)
Analysis of radial pressure wave forms allows for non-invasive estimation of central aortic pressures, accounting for pressure amplification and the amplitude of the arterial pulse wave as it moves through arteries away from the heart. The Atcor Sphygmacor system can derive central aortic pressures from radial tracings using a validated transfer function. This computation is performed using the pulse wave analysis (PWA) mode. Pulse Wave Analysis via radial tonometry was obtained as a measure of chronic exposure.
Time frame: v2 was generally 1-2 weeks after enrollment visit, with a window up to 4 weeks from V1
Exercise Treadmill Stress Test (ETT)-Peak METS
An ETT to determine exercise capacity will be completed as a measure of chronic exposure. Peak metabolic equivalents (METs, 1 MET=3.5 ml O2 uptake/kg body weight/minute) were determined at all exercise stages, peak exercise, and 1-minute post-exercise.
Time frame: Treadmill test done only once at the end of v2 after completion of all other post-challenge assessment tests. V2 was scheduled 1-4 weeks from enrollment vist
Diastolic Blood Pressure (DBP)
During V2, Diastolic Blood Pressure was measured using the oscillometric technique before an acute exposure challenge following a standardized protocol. After resting supine for 10 minutes blood pressure was measured on both arms and the average of the last two values was used. Participants attended v2 in the morning, fasting and refraining from nicotine products for at least 8 hours.
Time frame: V2 was generally 1-2 weeks after enrollment with a window up to 4 weeks from V1, recorded after resting supine for 10 minutes
Peak Rate Pressure Product (RPP, Peak Heart Rate Multiplied by Peak Systolic Blood Pressure)
Peak RPP was calculated by multiplying maximun heart rate during exercise by systolic blood pressure as a reliable assessment of cardiac workload
Time frame: During V2 (1-4 weeks after enrollment visit) the treadmill stress test was done last, following Nicotine-containing product challenge (users) or pretend 10 minute exposure for controls
Heart Rate Reserve (%)
Measure of maximal exercise capacity adjusted for age, calculated as max heart rate during treadmill divided by (220 minus the participant's age in yrs)
Time frame: During V2 (1-4 weeks after enrollment visit) the treadmill stress test was done last, following Nicotine-containing product challenge (users) or 10 minute pretend exposure for never-users
60 Seconds Heart Rate Recovery (Beats Per Minute)
Difference in heart rate 60 seconds post treadmill minus maximal heart rate during treadmill..
Time frame: During V2 (1-4 weeks after enrollment visit) the treadmill stress test was done last, following Nicotine-containing product challenge (users) or pretend 10 minute exposure for controls
March 5 2019 started enrollment, ended last visit March 9th 2022. Studies were conducted at the University of Wisconsin Hospital and Clinics and the Center for Tobacco Research and Intervention (CTRI) in Madison, WI and for a short period we also at CTRI location in Milwaukee,WI.
| Milestone | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Started | 139 | 192 | 119 |
| Completed | 117 | 164 | 114 |
| Not completed | 22 | 28 | 5 |
| Withdrew: Covid-19 shutdown period | 0 | 4 | 0 |
| Withdrew: Missed v2 visit- outside protocol window | 4 | 3 | 1 |
| Withdrew: Lost to follow-up | 8 | 0 | 2 |
| Withdrew: Did not qualify due to comorbidities, positive covid-9, high co, low co, negative nicotine in urine | 10 | 20 | 2 |
| Withdrew: While cleaning datasets, we realized one participant was enrolled twice. | 0 | 1 | 0 |
Brachial Artery Flow-Mediated Dilation is a primary cardiovascular biomarker and a measure of endothelial function that will be assessed before and after an acute exposure challenge. These are pre-challenge values. Ultrasound based changes in brachial artery diameter after a forearm cuff occlusion (250mmHg) for 5 minutes. FMD is the percent change in brachial diameter measured 60 to 90 seconds post cuff release compared to its resting diameter. A higher % dilation is an indication of better endothelial function.
| Percent change from resting diameter | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Brachial Artery Flow-Mediated Dilation (FMD)- Pre Challenge | 4.25 ± 3.17 | 4.89 ± 2.92 | 5.31 ± 3.43 |
FEV1 is a primary measure of pulmonary disease obtained by spirometry that will be assessed before and after an acute exposure challenge. These are per-challenge values
| percentage of volume exhaled | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Forced Expiratory Volume (FEV1)- Pre Challenge | 82.9 ± 18.9 | 93.8 ± 13.3 | 92.0 ± 13.4 |
Carotid Intima-Media Thickness is a cardiovascular biomarker and a measure of sub-clinical arterial injury and atherosclerosis as a result of chronic exposure. IMT will be measured via ultrasonography.
| mm | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Carotid Intima-Media Thickness (IMT) | 0.67 ± 0.18 | 0.54 ± 0.10 | 0.54 ± 0.10 |
Visit 2 was scheduled up to 4 weeks from enrollment visit, fasting.. They came in the morning after 8 hours of fasting and refraining from nicotine products. Systolic blood pressure (left brachial artery using an oscillometric method) was measured supine, after 10 minutes rest ("Pre") and repeated after they underwent smoking or vaping changes. The "post challenge" blood pressures were recorded 15-20 minutes post end of exposure. For controls, all measurements were repeated in the same order after a 10 minute break.
| mmHg | Never Users - Pre | Never Users-Post | Exclusive E-cigarette Users Pre Challenge | Exclusive E-cigarette Users Post-challenge | Exclusive Smokers Pre-challenge | Exclusive Smokers After Smoking Challenge |
|---|---|---|---|---|---|---|
| Changes in Systolic Blood Pressure Pre- and Post-challenge. | 118.4 ± 11.72 | 120.25 ± 12.00 | 119.74 ± 11.21 | 125.40 ± 11.54 | 126.43 ± 16.72 | 132.00 ± 16.09 |
Participants returned for V2 up to 4 weeks from enrollment visit, fasting. They came in the morning after 8 hours of fasting and refraining from nicotine products. Diastolic blood pressure (left brachial artery using an oscillometric method) was measured supine, after 10 minutes rest ("Pre") and repeated after they underwent smoking or vaping changes. The "post challenge" blood pressures were recorded 15-20 minutes post end of exposure. For controls, all measurements were repeated in the same order after a 10 minute break.
| mmHg | Never Users - Pre | Never Users-Post | Exclusive E-cigarette Users Pre Challenge | Exclusive E-cigarette Users Post-challenge | Exclusive Smokers Pre-challenge | Exclusive Smokers After Smoking Challenge |
|---|---|---|---|---|---|---|
| Changes in Diastolic Blood Pressure Pre- and Post-challenge. | 70.40 ± 7.13 | 72.51 ± 7.73 | 71.12 ± 7.52 | 75.31 ± 8.54 | 76.64 ± 10.72 | 81.04 ± 10.78 |
Visit 2 was scheduled up to 4 weeks from enrollment visit, fasting. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge heart rate measured supine, after 10 minutes rest from blood pressure monitor (dinamap). The post challenge heart rates were recorded 15-20 minutes post end of exposure to smoking or vaping challenge completion or in the case of controls after a 10 minute break.
| beats per minute (bpm) | Never Users - Pre | Never Users-Post | Exclusive E-cigarette Users Pre Challenge | Exclusive E-cigarette Users Post-challenge | Exclusive Smokers Pre-challenge | Exclusive Smokers After Smoking Challenge |
|---|---|---|---|---|---|---|
| Changes in Heart Rate Pre- and Post-challenge. | 59.57 ± 8.19 | 58.42 ± 7.88 | 58.34 ± 9.22 | 63.17 ± 10.13 | 65.31 ± 11.65 | 69.15 ± 12.05 |
Visit 2 was scheduled up to 4 weeks from enrollment visit. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge brachial artery diameter imaged with ultrasound after resting supine for 10 minutes before and repeated 15-20 minutes after smoking/vaping challenge ended. or in the case of controls after a 10 minute break.
| centimeters (cm) | Never Users - Pre | Never Users-Post | Exclusive E-cigarette Users Pre Challenge | Exclusive E-cigarette Users Post-challenge | Exclusive Smokers Pre-challenge | Exclusive Smokers After Smoking Challenge |
|---|---|---|---|---|---|---|
| Changes in Brachial Artery Diameter Pre- and Post-challenge | 0.378 ± 0.062 | 0.370 ± 0.063 | 0.388 ± 0.064 | 0.378 ± 0.063 | 0.410 ± 0073 | 0.398 ± 0.068 |
Visit 2 was scheduled up to 4 weeks from enrollment visit. Participants attended fasting and refraining from nicotine products for at least 8 hours prior. All visits were in the morning. Pre-challenge ultrasound of brachial artery diameter imaged with ultrasound after resting supine for 10 minutes before and repeated 15-20 minutes after smoking/vaping challenge ended. or in the case of controls after a 10 minute break. The FMD protocol includes measuring % change in resting diameter after 60-90 seconds post fore-arm cuff occlusion release.
| percent change | Never Users - Pre | Never Users-Post | Exclusive E-cigarette Users Pre Challenge | Exclusive E-cigarette Users Post-challenge | Exclusive Smokers Pre-challenge | Exclusive Smokers After Smoking Challenge |
|---|---|---|---|---|---|---|
| Changes in Brachial Artery Flow Mediated Dilation (FMD) Pre- and Post-challenge | 5.31 ± 3.43 | 4.22 ± 3.01 | 4.89 ± 2.92 | 4.62 ± 3.52 | 4.25 ± 3.17 | 3.57 ± 2.26 |
Expressed as a percentage of beats (supine recordings had be 5 minutes or longer to be valid). We used the SphygmoCor system for these recordings (Atcor medical). Participants attended V2 1-2 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability was recorded supine for 10 minutes or more, pre and post smoking/vaping challenge. For controls is was repeated after a 10-minute break.
| percent of sequential intervals | Never Users - Pre | Never Users-Post | Exclusive E-cigarette Users Pre Challenge | Exclusive E-cigarette Users Post-challenge | Exclusive Smokers Pre-challenge | Exclusive Smokers After Smoking Challenge |
|---|---|---|---|---|---|---|
| Changes in Percent of Sequential Heart Cycles That Differ by More Than 50 ms From Each Other in Length (PNN50, %) Pre- and Post-challenge | 33.64 ± 20.83 | 36.46 ± 21.96 | 34.82 ± 21.85 | 31.02 ± 22.90 | 18.46 ± 19.72 | 15.45 ± 18.61 |
Participants attended V2 up to 4 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability was recorded supine for 10 minutes or more, pre and post smoking/vaping challenge. For controls it was repeated after a 10 minute break.
| milliseconds | Never Users - Pre | Never Users-Post | Exclusive E-cigarette Users Pre Challenge | Exclusive E-cigarette Users Post-challenge | Exclusive Smokers Pre-challenge | Exclusive Smokers After Smoking Challenge |
|---|---|---|---|---|---|---|
| Changes in Root Mean Square of Successive Differences Between Normal Heart Beats (RMSSD, ms) Pre- and Post-challenge | 66.44 ± 34.49 | 71.10 ± 38.78 | 71.20 ± 44.42 | 64.40 ± 46.33 | 48.29 ± 35.01 | 44.44 ± 38.73 |
We used the SphygmoCor system for these recordings (Atcor medical). Participants attended V2 up to 4 weeks after enrollment visit. They came in the morning fasting and refraining from nicotine for at least 8 hours. Heart rate variability standing ratio was assessed pre and post smoking/vaping challenge. For controls is was repeated after a 10-minute break. Ratio between maximal heart rate after abrupt standing from a supine position and the subsequent lowest heart rate value within 40 seconds of peak.
| ratio (unitless) | Never Users - Pre | Never Users-Post | Exclusive E-cigarette Users Pre Challenge | Exclusive E-cigarette Users Post-challenge | Exclusive Smokers Pre-challenge | Exclusive Smokers After Smoking Challenge |
|---|---|---|---|---|---|---|
| Changes in Heart Rate Variability Standing Ratio Pre- and Postchallenge | 1.57 ± 0.26 | 1.55 ± 0.22 | 1.55 ± 0.23 | 1.51 ± 0.23 | 1.38 ± 0.21 | 1.34 ± 0.23 |
maximum amount of air that the subject can forcibly expel during the first second following maximal inhalation, expressed as a percentage of the predicted normal values in the population. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
| predicted percentage of population | Never Users - Pre | Never Users-Post | Exclusive E-cigarette Users Pre Challenge | Exclusive E-cigarette Users Post-challenge | Exclusive Smokers Pre-challenge | Exclusive Smokers After Smoking Challenge |
|---|---|---|---|---|---|---|
| Changes in Predicted Forced Expiatory Volume in 1 Second (FEV1, %) Pre- and Post-challenge | 92.00 ± 13.41 | 91.12 ± 14.13 | 93.83 ± 13.32 | 89.76 ± 15.63 | 82.91 ± 18.90 | 80.43 ± 18.25 |
Amount of air that can be forcibly exhaled after taking the deepest breath possible expressed as a predicted percentage from the normal population. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
| predicted percentile | Never Users - Pre | Never Users-Post | Exclusive E-cigarette Users Pre Challenge | Exclusive E-cigarette Users Post-challenge | Exclusive Smokers Pre-challenge | Exclusive Smokers After Smoking Challenge |
|---|---|---|---|---|---|---|
| Changes in Forced Vital Capacity (FVC, %) Pre- and Post-Challenge. | 96.45 ± 15.06 | 95.00 ± 14.19 | 98.25 ± 13.50 | 96.77 ± 15.79 | 90.28 ± 15.99 | 87.88 ± 16.55 |
The post challenge spirometry was recorded \<15 minutes post end of exposure. Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
| ratio (unitless) | Never Users - Pre | Never Users-Post | Exclusive E-cigarette Users Pre Challenge | Exclusive E-cigarette Users Post-challenge | Exclusive Smokers Pre-challenge | Exclusive Smokers After Smoking Challenge |
|---|---|---|---|---|---|---|
| Changes in Ratio Between Predicted Forced Expiatory Volume in First Second and Predicted Total Vital Capacity (FEV1/FVC Ratio) Pre- and Post-challenge | 95.74 ± 9.63 | 95.93 ± 8.28 | 95.66 ± 8.90 | 92.23 ± 11.67 | 91.18 ± 12.56 | 90.89 ± 11.12 |
Participants attended Visit 2 (1-4 weeks after enrollment visit). They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge spirometry was performed sitting before all other tests and repeated within 15 minutes after smoking/vaping challenge.
| predicted percentile | Never Users - Pre | Never Users-Post | Exclusive E-cigarette Users Pre Challenge | Exclusive E-cigarette Users Post-challenge | Exclusive Smokers Pre-challenge | Exclusive Smokers After Smoking Challenge |
|---|---|---|---|---|---|---|
| Changes in Percent Predicted Forced Expiratory Flow at 25 and 75% of the Pulmonary Volume (FEF 25-75, %) Pre and Pos-challenge | 86.91 ± 27.33 | 85.17 ± 25.68 | 87.94 ± 23.45 | 80.20 ± 23.35 | 71.09 ± 31.09 | 68.49 ± 27.12 |
Participants attended V2 1-4 weeks after enrollment. They came in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior. Pre-challenge FeNO was obtained sitting and repeated within 15 minutes after smoking/vaping challenge.
| parts per billion (ppb) | Never Users - Pre | Never Users-Post | Exclusive E-cigarette Users Pre Challenge | Exclusive E-cigarette Users Post-challenge | Exclusive Smokers Pre-challenge | Exclusive Smokers After Smoking Challenge |
|---|---|---|---|---|---|---|
| Changes in Fractional Exhaled Nitric Oxide (FeNO, Ppb) Pre- and Post-challenge | 16.17 ± 11.04 | 16.97 ± 12.52 | 14.51 ± 14.71 | 13.64 ± 14.47 | 9.67 ± 12.26 | 9.93 ± 11.84 |
Heart Rate pre-acute exposure challenge was obtained after resting supine for 10 minutes during V2 in the morning, fasting and refraining from nicotine exposure for at least 8 hours prior.
| beats/minute | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Heart Rate (HR) | 65.3 ± 11.7 | 58.3 ± 9.2 | 59.6 ± 8.2 |
Heart Rate Variability PNN50(%) measured before an exposure challenge. Participants attended visit 2 fasting and refraining from nicotine for at least 8 hours.
| percentage of intervals | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Heart Rate Variability (HRV) - Pre Product Use Challenge | 11.4 (2.3 to 27.95) | 37.1 (15.0 to 51.98) | 31.0 (16.05 to 48.80) |
Blood Pressure measured using the oscillometric technique before an acute exposure challenge following standardized protocol. After resting supine for 10 minutes blood pressure was measured on both arms and the average of the last two values was used.
| mmHg | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Systolic Blood Pressure (BP) | 126.4 ± 16.7 | 119.7 ± 11.2 | 118.4 ± 11.7 |
Forced Vital Capacity is a measure of how much air can be exhaled forcefully obtained by spirometry pre acute exposure challenge.
| Percent predicted FVC | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Forced Vital Capacity (FVC) | 90.3 ± 16 | 98.3 ± 13.5 | 96.5 ± 15.1 |
Fractional Exhaled Nitric Oxide is a measure of airway inflammation measured before an acute exposure challenge.
| ppb | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Fractional Exhaled Nitric Oxide (FeNO) | 9.7 ± 12.3 | 14.5 ± 14.7 | 16.2 ± 11 |
Root mean square of standard deviation of rr intervals. Obtained fasting and refraining from nicotine exposure using the Sphymocor system. We used 10 or more minutes of supine data to derive heart rate variability measures.
| ms | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Autonomic Measures - RMSSD | 43.6 (25.95 to 56.20) | 63.3 (40.60 to 89.50) | 58.3 (41.40 to 82.80) |
Analysis of radial pressure wave forms allows for non-invasive estimation of central aortic pressures, accounting for pressure amplification and the amplitude of the arterial pulse wave as it moves through arteries away from the heart. The Atcor Sphygmacor system can derive central aortic pressures from radial tracings using a validated transfer function. This computation is performed using the pulse wave analysis (PWA) mode. Pulse Wave Analysis via radial tonometry was obtained as a measure of chronic exposure.
| percentage of central pulse pressure | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Arterial Pulse Wave Analysis (PWA), Augmentation Index (at 75 Bpm, %) | 19.5 (7.25 to 29.00) | 0.50 (-8.50 to 12.00) | 1.00 (-9.00 to 11.13) |
An ETT to determine exercise capacity will be completed as a measure of chronic exposure. Peak metabolic equivalents (METs, 1 MET=3.5 ml O2 uptake/kg body weight/minute) were determined at all exercise stages, peak exercise, and 1-minute post-exercise.
| METS | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Exercise Treadmill Stress Test (ETT)-Peak METS | 8.39 ± 3.19 | 10.29 ± 2.01 | 11.06 ± 2.42 |
During V2, Diastolic Blood Pressure was measured using the oscillometric technique before an acute exposure challenge following a standardized protocol. After resting supine for 10 minutes blood pressure was measured on both arms and the average of the last two values was used. Participants attended v2 in the morning, fasting and refraining from nicotine products for at least 8 hours.
| mmHg | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Diastolic Blood Pressure (DBP) | 76.6 ± 10.7 | 71.1 ± 7.5 | 70.4 ± 7.1 |
Peak RPP was calculated by multiplying maximun heart rate during exercise by systolic blood pressure as a reliable assessment of cardiac workload
| mmHg x bpm | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Peak Rate Pressure Product (RPP, Peak Heart Rate Multiplied by Peak Systolic Blood Pressure) | 249.99 ± 62.82 | 284.76 ± 51.36 | 290.86 ± 48.61 |
Measure of maximal exercise capacity adjusted for age, calculated as max heart rate during treadmill divided by (220 minus the participant's age in yrs)
| percentage of heart rate reserve | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Heart Rate Reserve (%) | 83.25 ± 11.58 | 87.89 ± 8.81 | 91.72 ± 7.58 |
Difference in heart rate 60 seconds post treadmill minus maximal heart rate during treadmill..
| beats per minute (bpm) | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| 60 Seconds Heart Rate Recovery (Beats Per Minute) | 19.62 ± 10.38 | 26.74 ± 9.06 | 28.06 ± 8.26 |
Collected over 2 years. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Exclusive Smokers | 0/117 (0%) | 0/117 (0%) | 0/117 (0%) |
| Exclusive E-Cig Users | 0/164 (0%) | 0/164 (0%) | 1/164 (0.6%) |
| Never Users | 0/114 (0%) | 0/114 (0%) | 1/114 (0.9%) |
| Event | Exclusive Smokers | Exclusive E-Cig Users | Never Users |
|---|---|---|---|
| Vasovagal responseGeneral disorders | 0/117 | 0/164 | 1/114 |
| NauseaGastrointestinal disorders | 0/117 | 1/164 | 0/114 |
results are reported for only those participants who completed the final study visit, when outcome data was collected.
| Age, Continuous(years) | Exclusive Smokers | Exclusive E-Cig Users | Never Users | Total |
|---|---|---|---|---|
| Mean | 42.8 ± 13.8 | 27.4 ± 10.6 | 30.8 ± 11.9 | 32.9 ± 13.6 |
| Sex: Female, Male(Participants) | Exclusive Smokers | Exclusive E-Cig Users | Never Users | Total |
|---|---|---|---|---|
| Female | 52 | 64 | 57 | 173 |
| Male | 65 | 100 | 57 | 222 |
| Ethnicity (NIH/OMB)(Participants) | Exclusive Smokers | Exclusive E-Cig Users | Never Users | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 5 | 6 | 12 |
| Not Hispanic or Latino | 115 | 159 | 108 | 382 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Exclusive Smokers | Exclusive E-Cig Users | Never Users | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 2 |
| Asian | 7 | 9 | 21 | 37 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 38 | 4 | 5 | 47 |
| White | 65 | 141 | 79 | 285 |
| More than one race | 5 | 9 | 9 | 23 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Exclusive Smokers | Exclusive E-Cig Users | Never Users | Total |
|---|---|---|---|---|
| United States | 117 | 164 | 114 | 395 |
| Exhaled CO(ppm) | Exclusive Smokers | Exclusive E-Cig Users | Never Users | Total |
|---|---|---|---|---|
| Mean | 16.11 ± 13.7 | 2.96 ± 1.89 | 2.79 ± 1.73 | 6.8 ± 9.7 |
| Serum Nicotine (ng/ml)(ng/ml) | Exclusive Smokers | Exclusive E-Cig Users | Never Users | Total |
|---|---|---|---|---|
| Mean | 4.48 ± 4.54 | 2.95 ± 2.58 | 1.99 ± 0.00 | 3.07 ± 3.07 |
| Serum Cotinine (ng/ml)(ng/ml) | Exclusive Smokers | Exclusive E-Cig Users | Never Users | Total |
|---|---|---|---|---|
| Mean | 231.3 ± 127.7 | 193.5 ± 111.7 | 2.99 ± 8.88 | 140.4 ± 141.0 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — Our plan includes the creation of a data archive with coded information in computer-readable form for distribution to the scientific community using the procedures outlined below. The information will include a codebook with definitions of variables, variable field locations, summary statistics and any standard scoring. Final data sets will be stripped of identifiers prior to release for sharing (the release of a limited data set containing one or more specific identifiers would be considered if absolutely required by the researcher and if the request meets all University of Wisconsin -Institutional Review Board and Office of Human Research Protections policies. We will make all key variables available via posting of final data codebook and dataset in suitable archives. All shared variables and datasets will be de-identified and approved for sharing by the University of Wisconsin and Institutional Review Board
Supporting information: Study protocol, Statistical analysis plan
Time frame: After data has been collected and analyzed.
Access criteria: In accord with an Institutional Review Board-approved study consent that will permit sharing of study data sets under University of Wisconsin and Institutional Review Board policies, University of Wisconsin Center for Tobacco Research and Intervention will act under its own auspices as the hub for making data related to these topics available. We will make the final de-identified study dataset available by request from other researchers in accord with NHLBI policy.
Data sharing details ↗ · www.ctri.wisc.edu
Ran from Mar 2019 to primary completion in Mar 2022, 36 months.
Results were first posted in Aug 2023, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Wisconsin, Madison →